Conference Track

Focus on Investigational HCV Agents

Source: CCO Independent Conference Coverage of the 2008 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

PROVE 1 Study: Combination Telaprevir, Peginterferon alfa-2a, and Ribavirin Therapy Has Rapid and Sustained Antiviral Activity in HCV Genotype 1 Patients
Factors Associated With High Barrier to R1626 Resistance Identified
High Response Rates When Telaprevir Added to Peginterferon alfa-2a/Ribavirin in Treatment-Naive, Genotype 1 HCV–Infected Patients
Intravenous Silibinin Demonstrates Significant Antiviral Activity in Peginterferon/Ribavirin Nonresponders With Chronic Hepatitis C
Once-Daily Dosing of TMC435350 Well Tolerated and Active in Patients With Hepatitis C
High RVR Rates, Good Safety Profile for R7128 When Combined With Peginterferon Alfa-2a/Ribavirin in Treatment-Naive Patients With HCV Genotype 1
Addition of Nitazoxanide to Peginterferon/Ribavirin Therapy Associated With Improved RVR, SVR in Genotype 4 HCV
Efficacy of Boceprevir-Based Therapy in Peginterferon/Ribavirin Null Responders Appears Limited to Those With Residual Responsiveness to Peginterferon/Ribavirin
Potent Viral Suppression After 1 Month of Debio-025/Peginterferon Therapy in Treatment-Naive HCV-Monoinfected Patients
High End-of-Treatment Response Rate With R1626 Triple Combination Therapy in Treatment-Naive Patients Infected With Genotype 1 HCV
Interim Analysis: High Response Rates With Boceprevir Plus Standard of Care in Treatment-Naive Patients With Genotype 1 HCV Infection
Taribavirin Demonstrated Comparable Early Efficacy, Less Anemia vs Ribavirin When Dosed According to Weight
Significant HCV RNA Decline by Week 4 With Telaprevir-Based Therapy in Previous Peginterferon/Ribavirin Genotype 1 Nonresponders, Null Responders, and Relapsers

Expert Analysis

Focus on Investigational HCV Agents

Faculty:

Nezam H. Afdhal, MD, FRCPI
Ira M. Jacobson, MD
Stefan Zeuzem, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize data on the use of protease inhibitors in treatment-naive and nonresponder patients with genotype 1 chronic hepatitis C
Recount data on novel polymerase inhibitors for the treatment of genotype 1 chronic hepatitis C
Describe the importance of ribavirin in treating chronic hepatitis C and the role of ribavirin analogues
Describe new data on novel classes of drugs for the treatment of chronic hepatitis

CREDIT INFORMATION

Release Date: June 20, 2008

Expiration Date: June 19, 2009

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.2 Nursing contact hours

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.